If you recently took advantage of the United States' National Institute on Drug Abuse's (NIDA) program offering free genotyping on our Smokescreen® genotyping array to substance abuse disorder investigators, remember to also take advantage of our full suite of services for clinical trials using biological markers (biomarkers). You can also learn more about Smokescreen in BMC Genomics.

 

Designed specifically for researchers interested in the causes of addiction and its treatment.

More addiction-related content than any other commercially available array

  • Covers 98% of common genetic variation in 1000+ addiction genes

  • More than 296K markers, selected for African, East Asian, and European populations

  • More than 20K markers from expert nomination, knowledge-bases, candidate gene arrays, and the literature

More nicotine and tobacco related content than any other commercially available array

  • More than 11K markers in the nicotine acetylcholine receptor gene cluster3 and nicotine metabolizer regions4
  • More than 16K markers for related co-morbidities and diseases

Better genome-wide imputation coverage of common variants than most similarly-sized arrays

  • African (66%), East Asian (82%), and European (91%)
The Smokescreen® genotyping array  is comprehensive, cost-efficient, cutting-edge, easy to use, elegant, and powerful. 

The Smokescreen® genotyping array  is comprehensive, cost-efficient, cutting-edge, easy to use, elegant, and powerful. 

1 Developed with support from the United States National Institute on Drug Abuse (NIDA).
2 For research use only. Not for use in diagnostic procedures.
3 CHRNA5-CHRNA3-CHRNB4
4 CYP2A6-CYP2B6